大江基因醫學股份有限公司 Approved
最後更新時間 2025/06/03 , 04:00 AM
最後更新時間 2025/06/03 , 04:00 AM
負責人
Lin,Yong-Xiang
統一編號
53357669
成立日期
2011/07/13
資本額
NT$500,000,000
實收資本額
NT$264,585,200
股票代號
6879
電話
#8100
地址
10-1F, No. 185, Gangcian Rd., Neihu Dist., Taipei City, 114, Taiwan
董監事
姓名 職稱 持有股份 代表法人
Lin,Yong-Xiang Chairman 42.05% TCI CO., LTD.
Fu,Zhen-Zhen Director 42.05% TCI CO., LTD.
COUNDE O'YANG Director 42.05% TCI CO., LTD.
Yang,Hong-Pei Director 17.84% Qisda Corporation
Lin,Shui-Yong Independent Director 0.00%
Sun,Wei-Xin Independent Director 0.00%
Zhang,Ke-Ying Independent Director 0.00%
營業項目
  • Wholesale of Other Food(454999)
  • Other Professional, Scientific and Technical Activities Not Elsewhere Classified(760999)
  • Management Consultancy Activities(702099)
  • Manufacture of Medicinal Biological Products(200300)
  • 公司歷程
  • Change Capital to 500,000,000
    2016/04/26
  • Change Capital to 100,000,000
    2015/09/16
  • Change Person in Charge to Lin,Yong-Xiang
    2015/09/16
  • Change Capital to 60,000,000
    2012/10/08
  • Change Person in Charge to Guan,Shu-Jun
    2012/05/16
  • 員工人數
    下載完整報告查看完整數據
    財務報表
    項目 2024 2023 2022
    Operating income 347,539 333,855 424,022
    Operating cost 143,470 159,238 180,663
    Profit (loss) of initial recognition of biological asset and agricultural products - - -
    Profit (loss) on changes in fair value less costs to sell of biological asset for current period - - -
    Operating gross profit (loss) 204,069 174,617 243,359
    Unrealized profit (loss) on sales of goods - - -
    Realized profit (loss) on sales of goods - - -
    Operating gross profit (loss), net 204,069 174,617 243,359
    Operating expenses 151,570 168,687 152,796
    Other gain (loss), net - - -
    Operating profit (loss) 52,499 5,930 90,563
    Non-operating income and expenses 15,058 2,845 -432
    Net profit (loss) before tax 67,557 8,775 90,131
    Income tax expense (benefits) 11,032 -8,179 15,794
    Net profit (loss) of ongoing business for the current period 56,525 16,954 74,337
    Profit (loss) of closed units - - -
    Profit (loss) of non-jointly controlled equity before merger - - -
    Net profit (loss) for the current period 56,525 16,954 74,337
    Other comprehensive profit (loss), net -43,293 17,214 10,497
    Comprehensive net profit and loss of non-jointly controlled equity before merger - - -
    Total comprehensive profit and loss for the current period 13,232 34,168 84,834
    Net profit (loss) attributable to owners of parent company 56,311 11,673 72,145
    Net profit (loss) form equity attributable to former owner of business combination under common control - - -
    Net profit (loss) attributable to non-controlling interests 214 5,281 2,192
    Comprehensive profit (loss) attributable to owners of parent company 11,675 25,325 80,471
    Comprehensive profit (loss) form equity attributable to former owner of business combination under common control - - -
    Comprehensive profit (loss) attributable to non-controlling interests 1,557 8,843 4,363
    Basic earnings per share (yuan) 2 0 2
    項目 2024 2023 2022
    Net cash inflow (outflow) from operating activities 56,966 17,849 110,353
    Net cash inflows (outflows) from investing activities -619,343 -203,862 -39,995
    Net cash inflow (outflow) from financing activities -35,523 -50,644 535,725
    Effect of Exchange Rate Changes on Cash and Cash Equivalents 280 -35 468
    Increase (decrease) in cash and cash equivalents in the current period -597,620 -236,692 606,551
    Beginning balance of cash and cash equivalents 696,046 932,738 326,187
    Ending balance of cash and cash equivalents 98,426 696,046 932,738
    項目 2024 2023 2022
    Current asset 994,284 1,068,720 1,076,053
    Non-current asset 104,819 97,220 87,276
    Total asset 1,099,103 1,165,940 1,163,329
    Current liability 101,291 155,548 143,169
    Non-current liability - - 0
    Total liability 101,291 155,548 143,169
    share capital 264,585 264,585 264,585
    Equity - secruity token - - -
    capital reserve 607,765 604,760 595,779
    retained earning 113,461 83,608 124,852
    Other equity -11,077 33,559 19,907
    Treasury stock - - -
    Total equity attributable to owners of parent company 974,734 986,512 1,005,123
    Equity attributable to former owner of business combination under common control - - -
    Equity attributable to non-controlling interest before business merger under common control - - -
    Non-controlling interests 23,078 23,880 15,037
    Total Equity 997,812 1,010,392 1,020,160
    Share capital awaiting retirement (unit: share) 0 0 0
    Issued shares of advance equity (unit: shares) 0 0 0
    Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) 0 0 0
    Net asset value per share 36 37 37
    動產抵押
    下載完整報告查看完整數據
    案件類別 債務人名稱 債務人統編 契約啟始日期 契約終止日期 抵押權人名稱 抵押權人統編 擔保債權金額
    選舉收入(政治獻金)
    收入名稱 收入金額
    總收入金額
    選舉支出(政治獻金)
    支出名稱 支出金額
    總支出金額
    標案拒往
    機關名稱 生效日期 截止日期
    進出口資料
    下載完整報告查看完整數據
    年份 月份 總進口實績(美金) 總出口實績(美金)
    商標
  • G2 BIOCHIP FOR ASIAN
  • 健樂士
  • R1 BIOCHIP FOR ASIAN
  • Slim8D 設計圖
  • G1 BIOCHIP FOR ASIAN
  • GeNext
  • 香港商健樂士有限公司標章
  • Slim 8D 設計圖
  • 健樂仕
  • GeNext GENE & NEXT INC
  • 專利
    政府標案
    標案名稱 機關名稱 決標日期 決標金額 是否得標
    裁判書查詢
    勞權違規
    日期 違反法規法條 罰鍰金額
    污染源裁處
    污染類別 裁處時間 裁處機關 裁處金額 違反事實 違反法令 裁處書字號 裁處理由及法令 公司地址
    本頁內所載之資料,所載資料之完整性、即時性和正確性仍應以資料來源單位為準。
    公司一有新動態,我們馬上通知你,追蹤公司讓你不錯過任何更新。